AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 164 min read$ALVONeutralMed

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech (NASDAQ: ALVO) priced a $152 million underwritten public offering of 22,666,667 ordinary shares at $3.75 each, expected to close June 17, 2026. Gross proceeds are about $85 million, rising to ~$98 million if underwriters buy an extra 3.4 million shares. A concurrent private placement will sell 17,826,666 shares for ~$67 million gross. Total gross proceeds: ~$152 million (~$165 million with the option).

AI DeskJune 16, 2026
Source · manilatimes.net
AI analysis
Relevance
8/10
Novelty
8/10
Actionability
Med
Sentiment · $ALVO
Neutral
Timing
ahead of expected June 17, 2026 closing (and June 25, 2026 for the private placement)
Market alignment
neutral-to-negative (dilution overhang)
Why this matters for $ALVO

Dilutive equity issuance at a fixed price; near-term trading likely driven by dilution math, use-of-proceeds credibility, and any underwriting/option size.

Relevance context

Alvotech priced a $152M underwritten public offering plus concurrent private placement at $3.75/share, with closing dates in June 2026.

Price-impact prediction

Likely near-term pressure/volatility around dilution expectations, partially offset if proceeds are viewed as funding high-visibility biosimilar development.

Background

Alvotech is a biosimilars company with multiple approved products and a disclosed pipeline; this release details a priced equity offering and concurrent exempt private placement.

Why it matters

The fixed $3.75/share price and total gross proceeds ($152M; $165M with option) create a clear dilution overhang, while stated use of proceeds frames the capital as funding continued biosimilar development and corporate needs.

Market relevance

A priced, sizable equity raise at a specific per-share price is a direct catalyst for ALVO’s near-term trading via dilution and closing-date mechanics.

Market effects

Sector

Biosimilar developers may face similar financing/dilution scrutiny; capital raises can shift sentiment toward pipeline-funded stories.

Regional

Limited direct regional impact beyond US-listed biotech financing flows.

Global

Proceeds earmarked for global biosimilar development could influence broader investor appetite for non-originator biologics.

Alternative perspectives

Contrarian view

If investors believe the $152M is sufficient to de-risk multiple pipeline milestones, the raise could be interpreted as strengthening long-term optionality despite dilution.

Overlooked factors

The underwriters’ 30-day option size (additional 3.4M shares) and the non-contingent structure vs. the private placement can affect near-term supply/demand dynamics into the closing windows.

Key entities

  • company
    Alvotech

    NASDAQ-listed biosimilars company pricing a public offering and concurrent private placement.

  • financial_advisor
    BofA Securities

    Joint book-running manager for the offering.

  • financial_advisor
    Jefferies

    Joint book-running manager for the offering.

  • financial_advisor
    Evercore ISI

    Joint book-running manager for the offering.

Read at source← All news

Related articles

JUN 18
$ALVOMed

Amended: Alvotech Announces $125 Mln Public Offering, Concurrent Private Placement

Alvotech (ALVO) said it is launching an underwritten public offering of ordinary shares and a concurrent private placement, not an IPO. Net proceeds are expected at about $125 million, to fund biosimilar development and general corporate purposes. Underwriters have a 30-day option to buy up to 15% more shares. BofA Securities, Jefferies and Evercore ISI are joint book-runners.

rttnews.com2 min
JUN 18
$ALVOMedAI 8/10

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech (NASDAQ: ALVO) said it closed its underwritten public offering on June 17, 2026, selling 26,066,667 ordinary shares at $3.75 each, including full exercise of the underwriters’ option for 3,400,000 additional shares. Gross proceeds to the company were about $98 million. A concurrent $67 million private placement of 17,826,666 shares is expected to close around June 25, bringing total gross proceeds to about $165 million.

finanznachrichten.de4 min
JUN 16
$ALVOMedAI 9/10

Alvotech Prices $152 Million Offering To Advance Biosimilar Portfolio; Stock Down

Alvotech (ALVO) priced a combined $152 million capital raise via an underwritten public offering and a concurrent private placement, according to the company. The public offering sells 22.67M shares at $3.75 each for about $85M gross proceeds (about $98M if underwriters’ option is exercised). A private placement sells 17.83M shares for about $67M. Net proceeds will fund biosimilar development and corporate needs; shares closed at $4.24 Monday.

rttnews.com4 min
JUN 16
$ALVOMedAI 8/10

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech (NASDAQ: ALVO) priced a $152 million public offering of 22,666,667 ordinary shares at $3.75 each, with an underwriters’ 30-day option to buy up to 3,400,000 more shares. Expected gross proceeds are about $85 million, or $98 million with the option. A concurrent private placement will sell 17,826,666 shares for about $67 million. Net proceeds will fund biosimilar development and corporate purposes.

portal.sina.com.hk4 min